Skip to main content Accessibility help
×
Hostname: page-component-848d4c4894-hfldf Total loading time: 0 Render date: 2024-05-06T07:59:43.043Z Has data issue: false hasContentIssue false

55 - Entacapone

Published online by Cambridge University Press:  06 October 2020

Stephen D. Silberstein
Affiliation:
Thomas Jefferson University, Philadelphia
Michael J. Marmura
Affiliation:
Thomas Jefferson University, Philadelphia
Hsiangkuo Yuan
Affiliation:
Thomas Jefferson University, Philadelphia
Stephen M. Stahl
Affiliation:
University of California, San Diego
Get access

Summary

THERAPEUTICS

Brands

• Comtan, Stalevo

Generic?

• No

Class

• Antiparkinson agent

Commonly Prescribed for

(FDA approved in bold)

Parkinsonism, including Parkinson’s disease (PD)

How the Drug Works

• Highly selective peripherally acting inhibitor of catechol-O-methyltransferase (COMT), an important enzyme in dopamine metabolism. Use with carbidopa-levodopa enables more levodopa to enter the brain and prevents the end-of-dose wearing-off seen in PD. Entacapone has less activity on COMT in the brain, meaning the drug is not considered centrally active

How Long Until It Works

• PD: hours to weeks

If It Works

• PD: a majority (58%) of patients taking 800 mg or more per day of levodopa will lower levodopa dose, on average by 25% of the total after starting entacapone

If It Doesn't Work

• If end-of-dose wearing-off does not improve with entacapone and levodopa, decrease the dosing interval, add a dopamine agonist or monoamine oxidase B (MAO-B) inhibitor, or consider neurosurgical options. For sudden, unpredictable wearing-off, consider apomorphine

Best Augmenting Combos for Partial Response or Treatment-Resistance

• Entacapone is used only as an adjunctive medication in PD with levodopa

• For dyskinesias, lower dose of levodopa or add a dopamine agonist

• Younger patients with bothersome tremor: anticholinergics may help

• For severe motor fluctuations and/or dyskinesias with good “on” time, functional neurosurgery is an option

• Amantadine may help suppress dyskinesias, although benefit is often short-lived

• Depression is common in PD and may respond to low-dose SSRIs

• Cognitive impairment/dementia is common in mid-late stage PD and may improve with acetylcholinesterase inhibitors

Tests

• None required

ADVERSE EFFECTS (AEs)

How the Drug Causes AEs

• COMT inhibition increases the level and duration of action of levodopa

Notable AEs

• (Entacapone alone) diarrhea (usually mild to moderate), dyspnea, weakness. May increase levodopa-related AEs such as dyskinesias, nausea, orthostatic hypotension, and hallucinations

Type
Chapter
Information
Essential Neuropharmacology
The Prescriber's Guide
, pp. 205 - 208
Publisher: Cambridge University Press
Print publication year: 2015

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

  • Entacapone
  • Stephen D. Silberstein, Thomas Jefferson University, Philadelphia, Michael J. Marmura, Thomas Jefferson University, Philadelphia, Hsiangkuo Yuan, Thomas Jefferson University, Philadelphia
  • Edited in consultation with Stephen M. Stahl, University of California, San Diego
  • Book: Essential Neuropharmacology
  • Online publication: 06 October 2020
  • Chapter DOI: https://doi.org/10.1017/9781316161753.056
Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

  • Entacapone
  • Stephen D. Silberstein, Thomas Jefferson University, Philadelphia, Michael J. Marmura, Thomas Jefferson University, Philadelphia, Hsiangkuo Yuan, Thomas Jefferson University, Philadelphia
  • Edited in consultation with Stephen M. Stahl, University of California, San Diego
  • Book: Essential Neuropharmacology
  • Online publication: 06 October 2020
  • Chapter DOI: https://doi.org/10.1017/9781316161753.056
Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

  • Entacapone
  • Stephen D. Silberstein, Thomas Jefferson University, Philadelphia, Michael J. Marmura, Thomas Jefferson University, Philadelphia, Hsiangkuo Yuan, Thomas Jefferson University, Philadelphia
  • Edited in consultation with Stephen M. Stahl, University of California, San Diego
  • Book: Essential Neuropharmacology
  • Online publication: 06 October 2020
  • Chapter DOI: https://doi.org/10.1017/9781316161753.056
Available formats
×